Psoriatic Arthritis
Clinical Trial Studies
Currently Recruiting |
||
|
Protocol |
Study Title |
Inclusion Summary |
|
M14-496 |
A phase 4, open-label randomised controlled study, comparing the effectiveness of adalimumab introduction and methotrexate dose escalation in patient’s with Psoriatic Arthritis |
Psoriatic arthritis diagnosis for 4 weeks Active arthritis First treatment course of methotrexate, duration of 4-36 weeks and dosage ≤15mg weekly If on oral corticosteroids, < 10mg daily |
|
CAIN 2366 |
A randomized, double-blind, active control, multicenter study to evaluate the efficacy at week 52 of subcutaneously administered Secukinumab monotherapy compared with subcutaneously administered Adalimumab monotherapy in patients with active psoriatic arthritis |
Psoriatic arthritis diagnosis for 6 months Active Psoriatic arthritis RF and CCP negative at screening Active plaque psoriasis Inadequate control of symptoms with NSAID’s If on oral corticosteroids, must be on stable dose < 10mg day Previous cDMARD treatment with inadequate/intolerable response and no Concurrent cDMARD administration |
|
1F-MC-RHCF |
A 52-week multicenter, randomized, open-label, parallel-group study, evaluating the efficacy and safety of Ixekizumab versus Adalimumab in patients with psoriatic |
Psoriatic arthritis diagnosis for 6 months Active Psoriatic arthritis Active plaque psoriasis Inadequate response when previously treated with 1 or more csDMARD’s |
Upcoming Studies |
||
|
Protocol |
Study Title |
Inclusion Summary |
|
M15-554 |
A phase 3, randomized, double-blind, study comparing ABT-494 to placebo in subjects with active psoriatic arthritis who have a history of inadequate response to at least one biologic disease modifying anti-rheumatic drug (bDMARD) |
Psoriatic arthritis diagnosis for 6 months Active Psoriatic arthritis >3 swollen and tender joints Active plaque psoriasis, or history of plaque psoriasis Inadequate response or intolerance to 1 bDMARD If on oral corticosteroids, stable dose < 10mg daily |